ASSESSING THE OPTIMAL MAP TARGET IN PRE-CAPILLARY PH PATIENTS WITH RV FAILURE: A RETROSPECTIVE ANALYSIS

被引：0
|
作者：
Moallem, Niala
Fiscus, Garrett
Parikh, Raj
O'Sullivan, David M.
Perkins, Michael
Scatola, Andrew
机构：
来源：
CHEST | 2023年 / 164卷 / 04期
关键词：
D O I：
10.1016/j.chest.2023.07.3794
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：5890A / 5891A
页数：2
相关论文
共 18 条
  • [1] Assessing the optimal MAP target in pre-capillary PH patients with RV failure: A retrospective analysis
    Moallem, Niala
    Fiscus, Garrett
    O'Sullivan, David M.
    Perkins, Michael
    Scatola, Andrew
    Parikh, Raj
    PULMONARY CIRCULATION, 2023, 13 (04)
  • [2] Regression of RV mass and interventricular septal curvature duration predict mortality in patients with pre-capillary pulmonary hypertension: a follow up study
    Grapsa, J.
    Tan, T. C.
    Howard, L. S. G. E.
    Dawson, D.
    Gibbs, J. S. R.
    Picard, M. H.
    Nihoyannopoulos, P.
    EUROPEAN HEART JOURNAL, 2016, 37 : 1187 - 1187
  • [3] Pulmonary vascular response to exercise in heart-failure patients with pulmonary hypertension: role of a pre-capillary component
    Taylor, Bryan
    Johnson, Bruce
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [4] Simple parameters predict combined post- and pre-capillary pulmonary hypertension in patients with severe heart failure
    Lesny, P. Peter
    Luknar, M.
    Simovicova, V.
    Kovacova, M.
    Dankova, M.
    Wimmerova, S.
    Goncalvesova, E.
    EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 : 147 - 147
  • [5] Characteristics of Cardiopulmonary Exercise Testing in Patients with Combined Post-capillary and Pre-capillary Pulmonary Hypertension (Cpc-PH) Due to Left Heart Disease
    Goda, A.
    Takeuchi, K.
    Kikuchi, H.
    Inami, T.
    Satoh, T.
    Yoshino, H.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2018, 37 (04): : S491 - S492
  • [6] Clinical and echocardiographic characteristics of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction or with pre-capillary pulmonary hypertension
    Berthelot, E.
    Montani, D.
    Jais, X.
    Dreyfuss, C.
    Rifai, R.
    Bouchachi, A.
    Humbert, M.
    Simonneau, G.
    Sitbon, O.
    Assayag, P.
    EUROPEAN HEART JOURNAL, 2015, 36 : 784 - 784
  • [7] Therapeutic potential of phosphodiesterase 5 inhibitors in patients with heart failure with preserved ejection fraction (HFpEF) and combined post- and pre-capillary pulmonary hypertension (Cpc-PH).
    Kramer, T.
    Orlova, K.
    Gerhardt, F.
    Dumitrescu, D.
    Ten Freyhaus, H.
    Baldus, S.
    Rosenkranz, S.
    EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 : 531 - 531
  • [8] Therapeutic effects of phosphodiesterase 5 inhibitors in patients with heart failure with preserved ejection fraction (HFpEF) and combined post-and pre-capillary pulmonary hypertension (Cpc-PH)
    Kramer, T.
    Orlova, K.
    Gerhardt, F.
    Dumitrescu, D.
    Ten Freyhaus, H.
    Baldus, S.
    Rosenkranz, S.
    EUROPEAN HEART JOURNAL, 2017, 38 : 545 - 546
  • [9] Phosphodiesterase-type 5 Inhibition for Refractory Pre-capillary PH in Advanced Heart Failure is Associated with Increased Early Mortality Post Heart Transplant
    Ayers, M.
    Clark, K. A.
    Mazurek, J. A.
    Zamani, P.
    Fox, A.
    Forde-McLean, R.
    Rame, J. E.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2018, 37 (04): : S418 - S419
  • [10] Impact of PH-specific Therapy on Exercise Capacity and Mortality in Patients with pre-capillary pulmonary Hypertension with mPAP between 21-24 mmHg
    Yogeswaran, A.
    da Rocha, Brito B.
    Rako, Z.
    Zedler, D.
    Ghofrani, H.
    Fuenderich, M.
    Seeger, W.
    Gall, H.
    Richter, M.
    Kremer, N.
    Tello, K.
    PNEUMOLOGIE, 2024, 78 : S55 - S56
12